Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

This study will examine the effects of an oral Activator Ligand administration to modulate the timing of gene expression of human IL-12 by adenovirus-transduced dendritic cells injected into tumors.